Cassava Sciences, based in the USA, is a pharmaceutical company with an ESG score of 35.8, indicating high risk. Specializing in the development of treatments for Alzheimer's disease, they are known for their innovative product simufilam. Their investigational diagnostic tool, SavaDx, aims to detect Alzheimer's disease early through blood samples. Currently, Cassava Sciences is conducting Phase 3 clinical trials for simufilam to treat Alzheimer's disease dementia.